“USAP’s founding purpose, driven by Welsh Carson, was hardly subtle. Rather than building a new anesthesia practice from scratch, the newly minted corporation wanted to ‘consolidate practices with high market share’ in a select few localities—most prominently in Houston and Dallas.”

💡 Reveals the deliberate monopolistic intent from day one rather than organic growth or quality improvement.

“Internal communications apparently show how USAP and Welsh Carson referred to these gains as ‘synergies.’ For outsiders, that term might ring innocuous, but in the words of the FTC, USAP’s synergy meant forcibly levying the highest possible reimbursement rates and standardizing them across every acquired practice.”

💡 Corporate speak for synergies masked what the FTC characterizes as systematic price manipulation.

“Welsh Carson recognized that anesthesia, especially ‘hospital-only’ anesthesia, is among the few healthcare services that cannot be shopped around. When a person goes in for surgery, they have no realistic choice over who provides anesthesia in the operating room.”

💡 Explains why anesthesia was uniquely vulnerable to monopolistic exploitation and price increases.

“The FTC portrays Welsh Carson executives working hand-in-glove with USAP’s CEO and other top personnel, effectively calling the shots on USAP’s acquisitions, ‘pricing strategy,’ and overall approach to negotiating with payors.”

💡 Shows private equity directly controlled pricing decisions, undermining any claim this was about physician-led care improvement.

“When confronted with insurer pushback over the new, higher rates, USAP allegedly threatened to withdraw from insurance networks altogether, which would have forced payors to either pay ‘out-of-network’ prices (even higher than in-network) or risk a local uproar among employers and employees who rely on those hospitals.”

💡 Demonstrates how USAP leveraged exclusive hospital contracts to force insurers to accept inflated rates.

“One of the more blatant allegations is that USAP and a competitor simply agreed to carve up territory… If proven, such an agreement is a clear violation of antitrust law, as it runs counter to the fundamental principle of encouraging multiple competitors to serve patients in any given region.”

💡 Reveals alleged explicit collusion to divide markets and eliminate competition entirely in certain regions.

“Allegedly, USAP enticed them with an alternative arrangement—one that preserved the group’s separate identity on paper but let USAP bill for their anesthesia claims under USAP’s higher rates… The effect? Even if the other practice ‘never joined’ USAP or if the corporate structure was not merged, USAP unified the pricing.”

💡 Shows how USAP eliminated price competition even without formal acquisitions through creative billing arrangements.

“Each transaction—like adding a 50-physician group here or a 20-physician group there—often falls under certain reporting thresholds of the Hart-Scott-Rodino Act, which triggers federal pre-merger scrutiny… Yet collectively, they spelled the near-complete elimination of independent anesthesia groups in major Texas metropolitan areas.”

💡 Explains how systematic small acquisitions flew under regulatory radar while building monopoly power.

“The complaint describes how Welsh Carson has reaped hundreds of millions in dividend payments from USAP, paying back its initial investment many times over.”

💡 Quantifies the massive financial extraction that motivated the scheme.

“The day after filing its notice of appeal, USAP moved for a stay in district court, arguing that the pendency of the appeal stripped the district court of jurisdiction to conduct any proceedings, including discovery.”

💡 Reveals USAP’s litigation strategy to freeze the case while consumers continue paying inflated prices.

“USAP’s assertion that its claims on appeal somehow implicate ‘a right not to be tried’ is patently false… It would mean that USAP would potentially face trials in both fora.”

💡 FTC argues USAP’s appeal is procedurally improper and designed solely to delay accountability.

“Critically, this was not accompanied by a jump in labor costs for USAP or advanced patient technology. The shift was purely an exercise in using the new market leverage to demand and secure higher payments.”

💡 Refutes any claim that price increases reflected genuine cost increases or quality improvements.

“Texas consumers seeking anesthesia services throughout the State of Texas continue to pay inflated prices as a result of USAP’s anticompetitive conduct. The Court should not reward USAP’s abusive tactics.”

💡 FTC emphasizes real-time ongoing harm to patients while litigation drags on.

“Welsh Carson had already begun deploying a similar anesthesia ‘roll-up’ strategy in other specialties.”

💡 Suggests this was not an isolated incident but a broader private equity playbook for healthcare consolidation.

“The Supreme Court made crystal clear in Axon that ‘nothing we say today portends newfound enthusiasm for interlocutory review.’ This is a clear warning against exactly the kind of unduly expansive reading of the collateral order doctrine that USAP is now advocating.”

💡 FTC cites Supreme Court precedent against the type of delay tactic USAP is attempting.